A Novel Method of Vaccination Using Parasite Membrane Antigens
There have recently been a large number of vaccination studies using mouse models of cutaneous leishmaniasis. These have tended to use either whole attenuated organisms (Howard et al, 1982; Liew et al, 1985) or crude antigen preparations (Liew et al, 1985). Although these vaccine preparations increased resistance if inoculated intravenously (i.v.) or intra-peritoneally (i.p.), they exacerbated infections if administered subcutan-eously (s.c). Intravenous or i.p. vaccination procedures are obviously not acceptable for use with humans. Ideally a vaccine should comprise a purified biochemically defined antigen administered by a cutaneous or intramuscular route without any risk of exacerbating naturally acquired infections. Two antigens have been suggested as potential candidates for successful vaccination, the plasma membrane glycoprotein gp63 and the glycocon-jugate excreted factor (EF). Both antigens are involved in the attachment of the parasite to its host cell, the macrophage (Handman & Goding, 1985; Russell & Wilhelm, 1986), and are found in related forms in all species of Leishmania examined to date (Etges et al, 1985; Colomer-Gould et al, 1985; Handman et al, 1984). We describe here a novel means of presenting these antigens to the immune system and we have successfully vaccinated mice against L.mexicana by the s.c. route.
KeywordsCutaneous Leishmaniasis Lesion Diameter Vaccination Procedure Lesion Growth Adoptive Transfer Experiment
Unable to display preview. Download preview PDF.
- Chance, M.L., Schnur, L.F., Thomas, S. C. and Peters, W., 1978, The biochemical and serological taxonomy of Leishmania from the Aethiopian zoogeographical region of Africa, Ann.Trop.Med. and Parasitol., 72:533.Google Scholar
- Greenblatt, C. H., 1980, The present and future for cutaneous leishmaniasis, in: “New Developments with Human Vaccines”, A. Mizrahi, M. A. Kling-berg and A. Kohn, eds., Alan R. Liss, New York.Google Scholar
- Handman, E., Greenblatt, C. H., and Goding, J., 1984, An amphipathic sulphated glycoconjugate of Leishmania characterization with monoclonal antibodies, EMBO J., 3:1206.Google Scholar
- Kaye, P. M., 1987, Activation of cell-mediated immunity to Leishmania. 1. Primary T-cell activation detected by IL-2 receptor expression, Immunol., 61:345.Google Scholar
- Mayrink, W., Williams, P., DaCosta, C. A., Magalpaes, P. A., Melr, M. N., Dias, M., Oliveira Lima, A., Michaelick, M. S. M., Ferriera Carvahho, E., Barros, G. C., Sessa, P. A., and De Alencar, J. T. A., 1985, An experimental vaccine against American dermal leishmaniasis: experience in the State of Espirito Santo, Brazil, Ann.Trop.Med. Parasitol., 79:259.PubMedGoogle Scholar
- Russell, D. G., and Alexander, J., 1987, Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes, J.Immunol., submitted.Google Scholar